During the past decade, Institut Mutualiste Montsouris conducted 111 clinical trials. In the 10-year time frame, 111 clinical trials started and 8 clinical trials were completed, i.e. on average, 7.2% percent of trials that started reached the finish line to date. In the past 5 years, 48 clinical trials started and 7 clinical trials were completed. i.e. 14.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Mutualiste Montsouris" #1 sponsor was "Institut Mutualiste Montsouris" with 22 trials, followed by "GERCOR - Multidisciplinary Oncology Cooperative Group" with 14 trials sponsored, "UNICANCER" with 8 trials sponsored, "Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives" with 7 trials sponsored and "Hopital Foch" with 7 trials sponsored. Other sponsors include 97 different institutions and companies that sponsored additional 69 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Mutualiste Montsouris" #1 collaborator was "Institut National de la Santé Et de la Recherche Médicale, France" with 4 trials as a collaborator, "Ministry of Health, France" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "GERCOR - Multidisciplinary Oncology Cooperative Group" with 3 trials as a collaborator and "National Cancer Institute, France" with 3 trials as a collaborator. Other collaborators include 85 different institutions and companies that were collaborators in the rest 85 trials.

According to Clinical.Site data, the most researched conditions in "Institut Mutualiste Montsouris" are "Prostate Cancer" (13 trials), "Anorexia Nervosa" (5 trials), "Crohn's Disease" (5 trials), "Prostatic Neoplasms" (5 trials) and "Ulcerative Colitis" (5 trials). Many other conditions were trialed in "Institut Mutualiste Montsouris" in a lesser frequency.

Most popular intervention types in "Institut Mutualiste Montsouris" are "Drug" (64 trials), "Other" (35 trials), "Device" (33 trials), "Procedure" (26 trials) and "Biological" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Gemcitabine" (6 trials), "Pembrolizumab" (4 trials), "Enzalutamide" (3 trials) and "Ipilimumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Institut Mutualiste Montsouris" are 126 trials for "All" genders, 27 trials for "Male" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Institut Mutualiste Montsouris". 2 are not yet recruiting, 39 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 73 completed trials in Institut Mutualiste Montsouris, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Mutualiste Montsouris, 1 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 57 trials that are defined as “Not Applicable".

Institut Mutualiste Montsouris has several departments that took part in Clinical trials: "Institut Mutualiste Montsouris; Oncologie" - 4 trials, "Département d'Urologie, Institut Montsouris" - 2 trials